MX2020007881A - Formas cristalinas del antagonista del receptor cxcr7 acido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3- carbonil]-amino}-piperidin-3-carboxilico (1-pirimidin-2-il-ciclopr opil)-amida. - Google Patents

Formas cristalinas del antagonista del receptor cxcr7 acido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3- carbonil]-amino}-piperidin-3-carboxilico (1-pirimidin-2-il-ciclopr opil)-amida.

Info

Publication number
MX2020007881A
MX2020007881A MX2020007881A MX2020007881A MX2020007881A MX 2020007881 A MX2020007881 A MX 2020007881A MX 2020007881 A MX2020007881 A MX 2020007881A MX 2020007881 A MX2020007881 A MX 2020007881A MX 2020007881 A MX2020007881 A MX 2020007881A
Authority
MX
Mexico
Prior art keywords
crystalline forms
cyclopropylmethyl
pyrimidin
difluoro
cyclopropyl
Prior art date
Application number
MX2020007881A
Other languages
English (en)
Inventor
Raumer Markus Von
Philippe Guerry
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2020007881A publication Critical patent/MX2020007881A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La solicitud se refiere a formas cristalinas de ácido (33.4S)-1-ciclopropilmetil-4-0-(2A-difluoro-fenil)-isoxazol-3-car bonill-amino)-piperidin-3-carboxílco (1-pirimidin-2-il-ciclopropil )-amida: procesos para la preparación de las mismas y composiciones farmacéuticas que condenen tales formas cristalinas. El compuesto actúa como modulador de receptor CXCR7 y así es útil para el tratamiento del cáncer.
MX2020007881A 2018-01-26 2019-01-25 Formas cristalinas del antagonista del receptor cxcr7 acido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3- carbonil]-amino}-piperidin-3-carboxilico (1-pirimidin-2-il-ciclopr opil)-amida. MX2020007881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018051938 2018-01-26
PCT/EP2019/051819 WO2019145460A1 (en) 2018-01-26 2019-01-25 Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide

Publications (1)

Publication Number Publication Date
MX2020007881A true MX2020007881A (es) 2022-06-02

Family

ID=65139016

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007881A MX2020007881A (es) 2018-01-26 2019-01-25 Formas cristalinas del antagonista del receptor cxcr7 acido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3- carbonil]-amino}-piperidin-3-carboxilico (1-pirimidin-2-il-ciclopr opil)-amida.

Country Status (23)

Country Link
US (1) US11339148B2 (es)
EP (1) EP3743422B1 (es)
JP (1) JP7076010B2 (es)
KR (1) KR102502046B1 (es)
CN (1) CN111683945B (es)
AU (1) AU2019212888B8 (es)
BR (1) BR112020015024A2 (es)
CA (1) CA3088478A1 (es)
CL (1) CL2020001928A1 (es)
EA (1) EA202091746A1 (es)
ES (1) ES2976567T3 (es)
HR (1) HRP20240552T1 (es)
HU (1) HUE066704T2 (es)
IL (1) IL276227B1 (es)
MA (1) MA51664B1 (es)
MX (1) MX2020007881A (es)
PH (1) PH12020551121A1 (es)
PL (1) PL3743422T3 (es)
RS (1) RS65594B1 (es)
SG (1) SG11202006943TA (es)
TW (1) TWI822724B (es)
UA (1) UA125327C2 (es)
WO (1) WO2019145460A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019001042A (es) 2016-07-28 2019-06-10 Idorsia Pharmaceuticals Ltd Derivados de piperidina.
WO2021084068A1 (en) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE555087T1 (de) 2002-11-27 2012-05-15 Incyte Corp 3-aminopyrrolidinderivate als modulatoren von chemokinrezeptoren
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
WO2005032490A2 (en) 2003-10-08 2005-04-14 Bristol-Myers Squibb Company Cyclic diamines and derivatives as factor xa inhibitors
EP1853586B1 (en) 2005-02-18 2013-07-24 AstraZeneca AB Antibacterial piperidine derivatives
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
JP6094578B2 (ja) 2011-06-09 2017-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン
WO2013084241A1 (en) 2011-12-09 2013-06-13 Cadila Healthcare Limited Compounds as inhibitors of renin
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
ES2681593T3 (es) 2012-11-29 2018-09-14 Chemocentryx, Inc. Antagonistas de CXCR7
PT3004082T (pt) 2013-05-30 2017-11-13 Idorsia Pharmaceuticals Ltd Moduladores do receptor de cxcr7
ES2642074T3 (es) 2013-09-04 2017-11-15 Bristol-Myers Squibb Company Compuestos útiles como inmunomoduladores
ES2788848T3 (es) 2013-09-06 2020-10-23 Aurigene Discovery Tech Ltd Derivados de 1,2,4-oxadiazol como inmunomoduladores
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
SG10201901189SA (en) 2014-09-10 2019-03-28 Epizyme Inc Substituted piperidine compounds
EP3193604B1 (en) 2014-09-10 2021-06-16 Epizyme, Inc. Substituted n-(pyrrolidin-3-yl)isoxazole-3-carboxamide compounds
WO2016087370A1 (en) * 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Cxcr7 receptor modulators
MX2019001042A (es) * 2016-07-28 2019-06-10 Idorsia Pharmaceuticals Ltd Derivados de piperidina.

Also Published As

Publication number Publication date
ES2976567T3 (es) 2024-08-05
MA51664B1 (fr) 2024-05-31
PL3743422T3 (pl) 2024-07-01
SG11202006943TA (en) 2020-08-28
CN111683945B (zh) 2023-11-10
TWI822724B (zh) 2023-11-21
AU2019212888B2 (en) 2023-12-21
EP3743422B1 (en) 2024-03-13
US11339148B2 (en) 2022-05-24
EP3743422C0 (en) 2024-03-13
AU2019212888B8 (en) 2024-01-04
JP7076010B2 (ja) 2022-05-26
BR112020015024A2 (pt) 2021-01-19
KR20200116115A (ko) 2020-10-08
CN111683945A (zh) 2020-09-18
HUE066704T2 (hu) 2024-08-28
KR102502046B1 (ko) 2023-02-20
RS65594B1 (sr) 2024-06-28
PH12020551121A1 (en) 2021-05-31
AU2019212888A1 (en) 2020-09-10
EA202091746A1 (ru) 2020-11-26
CL2020001928A1 (es) 2020-12-18
JP2021511382A (ja) 2021-05-06
HRP20240552T1 (hr) 2024-07-19
IL276227B1 (en) 2024-06-01
IL276227A (en) 2020-09-30
CA3088478A1 (en) 2019-08-01
AU2019212888A8 (en) 2024-01-04
US20210115033A1 (en) 2021-04-22
EP3743422A1 (en) 2020-12-02
UA125327C2 (uk) 2022-02-16
TW201932460A (zh) 2019-08-16
MA51664A (fr) 2021-05-05
WO2019145460A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
CR20200588A (es) Compuestos novedosos
MX2020009957A (es) Compuestos para el tratamiento de enfermedad de hungtinton.
EA201990851A1 (ru) Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
EA200900658A1 (ru) Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами
EA200802119A1 (ru) Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат
CR20200413A (es) Inhibidores de canal de potencial de receptor transitorio de oxadiazol
EA200601273A1 (ru) Новая кристаллическая форма v агомелатина, способ её получения и фармацевтические композиции, которые её содержат
EA201992074A1 (ru) Фармацевтическая композиция, содержащая селексипаг
PH12020551121A1 (en) Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2023003264A (es) Inhibidores de cdk y su uso como productos fármaceuticos.
EP4331607A3 (en) Pharmaceutical composition containing 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide
MX2023007265A (es) Inhibidores de cdk y su uso como productos farmacéuticos.
MX2020012691A (es) Proceso para la sintesis del acido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxilico.
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
EA202090995A1 (ru) Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1
MX2023011829A (es) Derivados de uracilo como inhibidores de trpa1.
MX2021001804A (es) Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.
PH12021550258A1 (en) Cdk8/19 inhibitors
MX2022016357A (es) Derivados de tetrazol como inhibidores de trpa1.
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4